Log in

NASDAQ:FLDMFluidigm Stock Price, Forecast & News

$4.48
+0.14 (+3.23 %)
(As of 07/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.20
Now: $4.48
$4.80
50-Day Range
$3.48
MA: $4.18
$5.29
52-Week Range
$1.17
Now: $4.48
$12.26
Volume2.66 million shs
Average Volume1.74 million shs
Market Capitalization$316.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Read More
Fluidigm logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.24 million
Book Value$2.21 per share

Profitability

Net Income$-64,790,000.00

Miscellaneous

Employees535
Market Cap$316.78 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

How has Fluidigm's stock been impacted by COVID-19 (Coronavirus)?

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLDM shares have increased by 70.3% and is now trading at $4.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fluidigm?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fluidigm.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Fluidigm.

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) released its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.09. The medical research company had revenue of $27.62 million for the quarter. Fluidigm had a negative return on equity of 23.20% and a negative net margin of 48.20%. View Fluidigm's earnings history.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm issued an update on its first quarter 2020 After-Hours earnings guidance on Tuesday, April, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.6-27.6 million, compared to the consensus revenue estimate of $29.32 million.

What price target have analysts set for FLDM?

2 analysts have issued 12 month price targets for Fluidigm's shares. Their forecasts range from $7.00 to $9.00. On average, they expect Fluidigm's stock price to reach $8.00 in the next year. This suggests a possible upside of 78.6% from the stock's current price. View analysts' price targets for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

Media stories about FLDM stock have been trending negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fluidigm earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future. View the latest news about Fluidigm.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $4.48.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $316.78 million and generates $117.24 million in revenue each year. The medical research company earns $-64,790,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Fluidigm employs 535 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is www.fluidigm.com.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.